ESR2 and prostate cancer: Loss of ERβ in prostate cancer induces transcriptional down-regulation of prolyl hydroxylase 2, resulting in decreased HIF1-α hydroxylation, and thereby decreased ubiquitination by the von Hippel-Lindau tumor suppressor and increased HIF1α protein expression (85).